Baricitinib for Beta Cell Preservation in Newly Diagnosed Type 1 Diabetes

This study aims to determine if a medication called baricitinib can help maintain the function of beta cells in people who have recently been diagnosed with type 1 diabetes. Beta cells are responsible for producing insulin, which is crucial for managing blood sugar levels. The study focuses on individuals aged 1 to 35 years who have just been diagnosed with type 1 diabetes. By potentially preserving beta cell function, the study hopes to improve long-term health outcomes and manage diabetes more effectively for these patients. Participants in the study will receive either baricitinib or a placebo over a period of about 60 weeks. The treatment is given in a double-blind manner, meaning neither the participants nor the researchers know who is receiving the actual medication and who is getting the placebo. This approach helps ensure the results are unbiased. The main focus is to observe changes in beta cell function, which may influence how well the body can regulate blood sugar levels. As with any medical study, there may be risks and benefits associated with the treatment, which will be closely monitored by the research team.